Donate Toggle Menu


Issued: Wednesday, February 10, 2010 Philadelphia, PA

GlaxoSmithKline today announced the launch of CARES by GSK, a comprehensive program that
provides a single point of contact to GSK services and programs designed to improve access to GSK
oncology and specialty medications. In addition to the comprehensive offerings that include specialty
reimbursement services and free medicine, CARES by GSK now offers its first oncology co-pay
assistance program to further help eligible patients with limited insurance coverage to have better
access to GSK oral oncology and specialty medicines.

“It is becoming more and more difficult for patients and their providers to navigate today’s complex
healthcare system. Through CARES by GSK, we wanted to be a part of a solution that for the first
time streamlines access to the many services we offer, including a new co-pay assistance program,
so that patients can easily access the medicines that may help them,” said David Moules, vice
president, GlaxoSmithKline. “The program demonstrates our belief that improving access to needed
medicines is important.”

A range of services within the CARES by GSK program are now accessible via a single point of
contact, with counselors who will help patients who are prescribed GSK oncology and specialty
medicines. CARES by GSK counselors can verify benefits for patients with all types of insurance,
analyze insurance coverage, provide a co-pay forecast and research pharmacies that offer the lowest
available co-pays for each patient based on his or her insurance coverage. Counselors can also
administer co-pay assistance for patients on oral medications, explain the prior authorization process
for certain oral oncology and specialty medications, provide guidance for how to appeal denied and
underpaid claims, research foundations that provide patient assistance and support, and screen for
eligibility for GSK patient assistance programs that offer medicines at low or no cost, such as
Commitment to Access.

“Too often, patients encounter challenges to accessing their oncology medicines at all stages of the
process. We’ve collected feedback from patients through our existing programs and aimed to design
a new program to answer our patients’ needs,” said Sandy Moulton, director of GlaxoSmithKline
patient assistance and reimbursement. “We believe that CARES by GSK will make access to our
cancer and specialty medicines as helpful and simple a process as possible.”

GSK’s new co-pay assistance program is for people who have prescription coverage, but who need
extra help paying for their oral oncology and specialty medicines. Co-pays are based on patients’
need and reimbursement, and vary according to a sliding scale derived from the federal poverty level.
GSK also offers free GSK oncology and specialty prescription medications to eligible uninsured
patients. Patients with Medicare, commercial insurance, or other insurance who meet other
requirements can also qualify under certain circumstances.

For more information about CARES by GSK or to enroll, patients and their health care providers can
visit or call 1-888-ONE-GSKCARES.

GSK Patient Assistance Programs
GSK offers a number of additional programs to help patients get access to the non-oncology
medicines they need. Information about all of the programs can be found at The
programs are:

• Bridges to Access offers non-oncology medicines to eligible low-income patients who do not
have prescription drug benefits except Medicare Part D and generic-only coverage, and who
meet income eligibility requirements.

• GSK Access offers non-oncology medicines for eligible Medicare Part D enrollees who have
spent at least $600 on prescription medicines this year and who meet income eligibility

• Together Rx Access offers a free savings card program for those who are not eligible for
Medicare, do not have prescription coverage and who meet income eligibility requirements.
This program was created in 2005 by several pharmaceutical companies, including GSK, and
provides savings on more than 275 products. Together Rx Access information and
applications are available via or 1-800-444-4106.

GSK in Oncology
GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in
the lives of patients. Through GSK’s revolutionary ‘bench to bedside’ approach, we are transforming
the way treatments are discovered and developed, resulting in one of the most robust pipelines in the
oncology sector. Our worldwide research in oncology includes collaborations with more than 160
cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused
cancer treatments in prevention, supportive care, chemotherapy, and targeted therapies.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare
companies – is committed to improving the quality of human life by enabling people to do more, feel
better and live longer. For further information please visit

US Media Inquiries: Ken Inchausti (919) 483 2839
Kevin Colgan (919) 483 2839
Mary Anne Rhyne (919) 483 2839
Sarah Alspach (919) 483 2839
US Analyst/ Investor Inquiries: Tom Curry (215) 751 5419
Jen Hill Baxter (215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors
that any forward-looking statements or projections made by GSK, including those made in this announcement, are
subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that
may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual
Report on Form 20-F for 2008.

Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex